Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2024

Open Access 01-12-2024 | Human Papillomavirus | Research

Characteristics of human papillomavirus prevalence and infection patterns among women aged 25–64 according to age groups and cytology results in Ordos City, China

Authors: Sumeng Wang, Shujun Liu, Sensen Tan, Jian Yin, Yufei Li, Fanghui Zhao, Youlin Qiao

Published in: Virology Journal | Issue 1/2024

Login to get access

Abstract

Background

The assessment of human papillomavirus (HPV) genotype distribution in terms of age and cervical lesions could contribute to the adoption of more targeted preventive approaches to specific populations against cervical cancer. The current study was conducted in Ordos City, China, with the aim of analyzing the HPV genotypes prevalence and infection patterns within a hospital-based population.

Methods

The analysis included a total of 26,692 women aged 25–64 who underwent cervical cancer screening between January 1st, 2019, and June 30th, 2022, in Ordos City. These women had valid results for both the polymerase chain reaction (PCR)-reverse dot blot (RDB) HPV test and the liquid-based cytology (thinprep cytologic test/TCT). Data were extracted from the database of KingMed Diagnostics laboratories. The prevalence of HPV genotypes within different age groups and cytology diagnoses were calculated.

Results

Among 26,692 women, 7136 (26.73%) women were HPV positive, 5696 (21.34%) women were high-risk HPV (HR-HPV) positive, and 2102 (7.88%) women had multiple HPV infections. The most frequently detected HPV genotypes were HPV16 (4.72%) and HPV52 (4.15%), ranking as the first and second most prevalent genotypes, respectively. The prevalence of HR-HPV increased with age groups and severity of cervical lesions. Notably, the positive rate of HR-HPV among women aged 35–64 years showed a decreasing trend over the respective years, ranging from 26.00 to 19.70% (Ptrend < 0.001).

Conclusion

In conclusion, the epidemiology of HPV genotypes partly reflects the effectiveness of regional cervical cancer prevention and control efforts in the past. These findings can inform future initiatives concerning HPV vaccination and screening in the region.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China 2016. J Natl Cancer Center. 2022;5(38):1.CrossRef
3.
Kjær SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478–88.CrossRefPubMedPubMedCentral
4.
Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRefPubMed
5.
El Battioui F, El Malki F, Ghazal H, et al. Chapter 14—Progress in the development of vaccines against human papillomavirus. In: Ennaji MM, editor., et al., Oncogenic Viruses. London: Academic Press; 2023. p. 297–316.CrossRef
6.
7.
Poljak M, Oštrbenk VA, Gimpelj DG, et al. Commercially available molecular tests for human papillomaviruses: a global overview. Clin Microbiol Infect. 2020;26(9):1144–50.CrossRefPubMed
8.
Zeng Z, Austin RM, Wang L, et al. Nationwide prevalence and genotype distribution of high-risk human papillomavirus infection in china: analysis of 2,458,227 test results from 29 Chinese Provinces. Am J Clin Pathol. 2021;157(5):718–23.CrossRef
9.
Wagner M, Bennetts L, Patel H, et al. Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infect Agent Cancer. 2015;10:13.CrossRefPubMedPubMedCentral
10.
11.
Shujun Liu, Le Dang, Sumeng Wang, et al. Screening results and risk factors of cervical cancer among women aged 35–64 years old in Ordos of Inner Mongolia, 2016–2020. China Cancer 1–9.
12.
13.
14.
15.
Wang X, Song Y, Wei X, et al. Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China. Virol J. 2022;19(1):6.CrossRefPubMedPubMedCentral
16.
Jiang L, Tian X, Peng D, et al. HPV prevalence and genotype distribution among women in Shandong Province, China: analysis of 94,489 HPV genotyping results from Shandong’s largest independent pathology laboratory. PLoS ONE. 2019;14(1):e0210311.CrossRefPubMedPubMedCentral
17.
18.
Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23.CrossRefPubMed
19.
Wang R, Guo X-L, Wisman GBA, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257.CrossRefPubMedPubMedCentral
20.
Guo C, Du H, Qu X, et al. Prevalence of human papillomavirus among Chinese Han and Mongols Minor ity Women in Inner Mongolia, China: reflected by self-collected sample s in CHIMUST. Front Public Health. 2022;10:840879.CrossRefPubMedPubMedCentral
21.
Quek SC, Lim BK, Domingo E, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer. 2013;23(1):148–56.CrossRefPubMed
Metadata
Title
Characteristics of human papillomavirus prevalence and infection patterns among women aged 25–64 according to age groups and cytology results in Ordos City, China
Authors
Sumeng Wang
Shujun Liu
Sensen Tan
Jian Yin
Yufei Li
Fanghui Zhao
Youlin Qiao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2024
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02240-7

Other articles of this Issue 1/2024

Virology Journal 1/2024 Go to the issue

Review

Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

Research

Interference of pseudorabies virus infection on functions of porcine granulosa cells via apoptosis modulated by MAPK signaling pathways

Research

Analyzing factors affecting positivity in drive-through COVID-19 testing: a cross-sectional study

Research

Detecting the impacts of humidity, rainfall, temperature, and season on chikungunya, dengue and Zika viruses in Aedes albopictus mosquitoes from selected sites in Cebu city, Philippines

Research

Recombination analysis on the receptor switching event of MERS-CoV and its close relatives: implications for the emergence of MERS-CoV

Research

The POU-HD TFs impede the replication efficiency of several human papillomavirus genomes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits